Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2-PET in Breast Cancer Clinical Dilemma
NCT01832051Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2013
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 89Zr-trastuzumab in breast cancer, sponsored by University Medical Center Groningen. Primary endpoint: Concordance between HER2-PET results and anti-HER2 therapy at 2 years. Started Mar 2013; status: completed.
02
Drugs
89Zr-trastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01832051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01832051.